From the CMS document “Medicare Drug Price Negotiation Program: Select Drugs by Initial Price
Year of applicability 2027“:
On January 17, 2025, CMS announced the selection of the following list of 15 drugs covered under Medicare Part D for the second negotiating cycle (initial price applicability year 2027), based on total gross prescription drug costs covered under Medicare Part D and other criteria required by law.
With Trump’s inauguration taking place on Monday, will the Medicare drug price negotiation process change under the new administration? Anna Kaltenboeck points out in EndPoints News:
…the next administration will not have “general authority to change fundamental parts of the law,” certain aspects of the process can be changed without legislative action.
For example, CMS could alter its guidelines or how it interprets parts of the law, such as how many times it meets with drug makers or how many listening sessions it holds. “The degree to which they play hardball with manufacturers in the process could change,” he said.
